Study Title
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas (NCT01805037)
Trial description
The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin, also known as SGN-035, and rituximab) is in patients with certain types of lymphoma.
This study is for patients who have a type of lymphoma that expresses a tumor marker called CD30 and/or a type that is associated with the Epstein-Barr virus (EBV-related lymphoma) and who have not yet received any treatment for their cancer, except for dose-reduction or discontinuation (stoppage) of medications used to prevent rejection of transplanted organs (for those patients who have undergone transplantation). This study is investigating the combination of brentuximab vedotin and rituximab as a first treatment for lymphoma patients.
This trial is sponsored by Seattle Genetics/ Northwestern University. [1]
Study Data
- Condition: Lymphoma
- Interventions:
- Drugs used in this trial
- brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- rituximab (Rituxam®; Biogen, Inc,/ Genentech, Inc.)
- Other: laboratory biomarker analysis
- Drugs used in this trial
- Phase: I & II
- Estimated Enrollment: 33
- Start: March 2013
- Estimated Primary Completion: January 2016 (Final data collection date for primary outcome measure)
- Last verified: April 2015
Study Schematic
Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
